IOVANCE BIOTHERAPEUTICS, INC. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Friedrich-Reinhard Graf Finck von Finckenstein, M.D., Iovance's Chief Medical Officer since May 2019, separated on June 8, 2026, receiving a severance payment of $310,645.50 (net of withholdings). Effective June 9, 2026, he became a consultant at $300/hour (capped at $6,000/week) through December 9, 2026, with vested stock options' exercise period deferred until consulting term ends. The separation included a standard general release of claims.
Why this rating
Single executive departure routine for biotech; severance ~0.06% of market cap; consulting extension minimal. No indication of crisis or strategic shift; interim CEO already in place.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.